Drug intelligence / Profile preview

cyclosporine + varicella vaccine

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules, Vaccines & Immunotherapeutics
Administration
Oral, Subcutaneous
01

Overview

Cyclosporine + varicella vaccine is a combination of the immunosuppressant drug cyclosporine and the live attenuated varicella (chickenpox) vaccine. Cyclosporine acts primarily by inhibiting calcineurin, leading to suppression of T-cell activation and immune response. The live attenuated varicella vaccine stimulates both cell-mediated and humoral immunity against the varicella-zoster virus, providing protection against chickenpox or shingles. This combination has been studied in specific clinical contexts such as severe psoriasis, where adjunctive use of the vaccine with low-dose cyclosporine may modulate immune responses by influencing T helper 17 (Th17) and regulatory T cell (Treg) balance[4]. However, combining these agents is generally contraindicated due to increased risk of infection from live vaccines in immunosuppressed patients[3][6][8].

02

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)CN (Calcineurin)VZV (Varicella-zoster virus)

Beyond the preview

Go deeper on cyclosporine + varicella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine + varicella vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call